Live Breaking News & Updates on S An Indonesian Biopharmaceutical Start Up

JAKARTA, Indonesia, Sept. 28, 2022 /PRNewswire/ PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has secured B round of financing led by Yunfeng Capitaland followed by HighLight Capital. This round of financing will be mainly used for further strengthening the company's pipeline & licensing for new products, teams as well as capacity expansions. Etana is leading the development of the Indonesian biopharmaceutical industry and progressing to be the ASEAN leader in biopharmaceutical commercialization. Currently, Etana focus on local biopharmaceutical production for mRNA platforms, proteins and Monoclonal antibodies. Nathan Tirtana, Founder of Etana stated "Etana, as an Indonesian biopharmaceutical start-up, always strive to provide high quality, affordable and innovative biopharmaceutical products to serve the patients in Indonesia and South-East Asian countries. We will use the support obtained from the investors to develop local biopha ....

Hong Kong , Jakarta Raya , Nathan Tirtana , Indonesian Ulema Council , Business Services , Hong Kong Stock Exchange , Green Energy , Shanghai Shenzhen Stock Exchange , Biotechnologies Indonesia , Yunfeng Capital , South East Asian , Southeast Asian , Digital Agriculture , Wuxi Apptec , Highlight Capital , Shenzhen Stock Exchange , United Imaging , Sept 28 , 022 Prnewswire Pt Etana Biotechnologies Indonesia , N Indonesian Biopharmaceutical Company , As Securedb Round Of Financing Led By Yunfeng Capitaland Followed Highlight Capital This Will Be Mainly Used For Further Strengthening The Company 39s Pipeline Amp Licensing New Products , Eams As Well Capacity Expansions Etana Is Leading The Development Of Indonesian Biopharmaceutical Industry And Progressing To Be Asean Leader In Commercialization Currently , Tana Focus On Local Biopharmaceutical Production For Mrna Platforms , Roteins And Monoclonal Antibodies Nathan Tirtana , Ounder Of Etana Stated Quot , S An Indonesian Biopharmaceutical Start Up ,